Trial Profile
A Randomized, Double-Blind, Double-Dummy, Parallel Group 12-Week Comparison of the Efficacy and Safety of Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a Metered-Dose-Inhaler 230/42mcg Twice-daily With Fluticasone Propionate/Salmeterol DISKUS 250/50mcg Twice-daily in Subjects With COPD
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 28 Jun 2023
Price :
$35
*
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 29 Jun 2019 Results of post hoc analysis of exploratory genome-wide genetic analysis from 10 trials (NCT01772134, NCT01772147, NCT00633217, NCT01817764, NCT01879410, NCT01822899, NCT01323621, NCT01342913, NCT01323634, and NCT01706328)published in the Respiratory Medicine
- 19 May 2010 Results were reported at the 106th International Conference of the American Thoracic Society.
- 25 Mar 2009 Actual patient number (247) added as reported by ClinicalTrials.gov.